Predictors of Mortality in COVID‐19 Patients Presenting With Gastrointestinal Bleeding: A Retrospective Cross‐Sectional Study

ABSTRACT Background and Aims Coronavirus disease 2019 (COVID‐19), since its outbreak, has been a potentially fatal disorder. Gastrointestinal bleeding (GIB) with a notable prevalence of 1.5%–3% has been identified as a prominent cause of death in COVID‐19 patients. This study was conducted to evaluate GIB prevalence and mortality rate in COVID‐19 patients and to assess the role of potential risk factors on patient outcomes. Methods In this retrospective cross‐sectional study, the records of RT‐PCR confirmed COVID‐19 patients who presented with overt GIB symptoms (melena, hematochezia, and hematemesis) in their course of admission or hospitalization in Isfahan Shariati Hospital, between March 2020 and 2022, were enrolled. After exclusion, data on patients' demographics, comorbid conditions, manifestations of GIB, bleeding onset, and anticoagulant administration were extracted. Subjects were divided into two groups: alive and deceased 30 days after discharge to assess the role of variables on mortality. Results Among 7243 COVID‐19 patients, 107 (1.5%) individuals experienced GIB symptoms. After excluding patients with GIB not attributable to COVID‐19, 63 patients (0.86%) were included in the analysis, of whom 47.6% were reported deceased. The most common manifestations were hematemesis (42.9%) and melena (33.3%), indicating 76.2% of the upper GIB source. 61.9% of GIBs occurred during hospitalization, and the prevalence of hypertension, diabetes, and cardiovascular disease was 39.7%, 31.7%, and 19%, respectively. Endoscopic evaluation was performed in 12 patients, with gastric and duodenal ulcers being the most frequent findings (5 cases, 41.6%). Other than a significant association between the outcomes and the onset of bleeding ( p = 0.001, OR = 5.53), no statistically significant relationship was found among other variables. Conclusion GIB developing during hospitalization, as opposed to bleeding that occurred prior to admission, was suggested as a prognostic factor of mortality in COVID‐19 patients. Considering the fatal consequences of GIB in COVID‐19 patients, further studies are recommended to assess the roles of risk factors in preventing adverse outcomes.

Authors

Institutions

Publication Details

Journal
Health Science Reports
Published
2026-06-28
DOI
https://doi.org/10.1002/hsr2.72711
Primary Topic
Gastrointestinal Bleeding Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predictors of Mortality in COVID‐19 Patients Presenting With Gastrointestinal Bleeding: A Retrospective Cross‐Sectional Study

Hamid Mohajer, Elham Sabouri, Mobin Rasapour
Health Science Reports
Gastrointestinal Bleeding Diagnosis and Treatment
article

Predictors of Mortality in COVID‐19 Patients Presenting With Gastrointestinal Bleeding: A Retrospective Cross‐Sectional Study

Hamid Mohajer, Elham Sabouri, Mobin Rasapour
article en

Abstract

ABSTRACT Background and Aims Coronavirus disease 2019 (COVID‐19), since its outbreak, has been a potentially fatal disorder. Gastrointestinal bleeding (GIB) with a notable prevalence of 1.5%–3% has been identified as a prominent cause of death in COVID‐19 patients. This study was conducted to evaluate GIB prevalence and mortality rate in COVID‐19 patients and to assess the role of potential risk factors on patient outcomes. Methods In this retrospective cross‐sectional study, the records of RT‐PCR confirmed COVID‐19 patients who presented with overt GIB symptoms (melena, hematochezia, and hematemesis) in their course of admission or hospitalization in Isfahan Shariati Hospital, between March 2020 and 2022, were enrolled. After exclusion, data on patients' demographics, comorbid conditions, manifestations of GIB, bleeding onset, and anticoagulant administration were extracted. Subjects were divided into two groups: alive and deceased 30 days after discharge to assess the role of variables on mortality. Results Among 7243 COVID‐19 patients, 107 (1.5%) individuals experienced GIB symptoms. After excluding patients with GIB not attributable to COVID‐19, 63 patients (0.86%) were included in the analysis, of whom 47.6% were reported deceased. The most common manifestations were hematemesis (42.9%) and melena (33.3%), indicating 76.2% of the upper GIB source. 61.9% of GIBs occurred during hospitalization, and the prevalence of hypertension, diabetes, and cardiovascular disease was 39.7%, 31.7%, and 19%, respectively. Endoscopic evaluation was performed in 12 patients, with gastric and duodenal ulcers being the most frequent findings (5 cases, 41.6%). Other than a significant association between the outcomes and the onset of bleeding ( p = 0.001, OR = 5.53), no statistically significant relationship was found among other variables. Conclusion GIB developing during hospitalization, as opposed to bleeding that occurred prior to admission, was suggested as a prognostic factor of mortality in COVID‐19 patients. Considering the fatal consequences of GIB in COVID‐19 patients, further studies are recommended to assess the roles of risk factors in preventing adverse outcomes.

Health Science ReportsVol. 9(7)
Islamic Azad University of Najafabad (IR)
Good health and well-being
Openalex Percentile: Top 5%
Gastrointestinal Bleeding Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.